| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
MBN-305A does not have a specific biological or pharmacological target. As a cationic lipid, it functions as a delivery vehicle rather than a therapeutic agent with a defined molecular target. It is used to form liposomes and lipid nanoparticles for the encapsulation and delivery of nucleic acids such as siRNA, mRNA, and plasmid DNA. The cationic nature of the lipid allows it to complex with negatively charged nucleic acids through electrostatic interactions.
|
|---|---|
| ln Vitro |
In vitro, MBN-305A is used as a transfection reagent for delivering nucleic acids into cells. The cationic lipid forms liposomes or lipid nanoparticles that encapsulate nucleic acids and facilitate their uptake by cells through endocytosis. The compound's efficacy is evaluated based on transfection efficiency and cell viability in various cell lines. Detailed in vitro activity data for the lipid itself is not applicable as it is a delivery vehicle rather than a biologically active molecule.
|
| ln Vivo |
In vivo, MBN-305A is used as a component of lipid nanoparticle formulations for the delivery of therapeutic nucleic acids. The cationic lipid helps to encapsulate nucleic acids and protect them from degradation in the bloodstream. Lipid nanoparticles containing MBN-305A can be administered via intravenous or other routes to deliver nucleic acids to target tissues. The compound's in vivo performance is evaluated based on the efficacy of the encapsulated nucleic acid payload.
|
| Enzyme Assay |
Non-cellular assays for MBN-305A are not applicable as it is a lipid rather than an enzyme inhibitor or receptor ligand. The compound's physicochemical properties, such as its cationic charge and lipid bilayer-forming ability, can be characterized using standard techniques including dynamic light scattering, zeta potential measurements, and thin-layer chromatography. The purity and identity of the compound are confirmed by analytical methods such as NMR and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments involve using MBN-305A to formulate liposomes or lipid nanoparticles for nucleic acid delivery. Cells are treated with the formulations, and transfection efficiency is assessed by measuring the expression of a reporter gene or the knockdown of a target gene. Cell viability is measured to assess the cytotoxicity of the formulation. The compound's ability to facilitate cellular uptake of nucleic acids is evaluated by fluorescence microscopy or flow cytometry using labeled nucleic acids.
|
| Animal Protocol |
In vivo animal studies for MBN-305A involve the administration of lipid nanoparticle formulations containing therapeutic nucleic acids. The formulations are typically administered via intravenous injection. The efficacy of the encapsulated nucleic acid payload is evaluated by measuring relevant biomarkers or therapeutic endpoints. Biodistribution studies may be performed to assess the accumulation of the lipid nanoparticles in target tissues. The compound's safety and tolerability are also evaluated in these studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for MBN-305A as a standalone compound is limited. The compound has a molecular weight of 620.09 g/mol and a molecular formula of C₄₁H₈₁NO₂. It is a liquid at room temperature. As a component of lipid nanoparticles, its pharmacokinetics are determined by the overall formulation properties, including particle size, surface charge, and PEGylation.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for MBN-305A is limited. As a cationic lipid, it may cause cytotoxicity at high concentrations due to its positive charge. The compound is for research purposes only and should be handled with appropriate safety precautions. No LD₅₀ or specific toxicity information has been reported.
|
| References | |
| Additional Infomation |
MBN-305A (DODMA, 1,2-Dioleyloxy-3-(dimethylamino)propane) is a cationic lipid used in the preparation of liposomes and lipid nanoparticles for gene therapy and nucleic acid delivery applications. It is a synthetic compound that belongs to the family of cationic lipids, which are commonly used as non-viral vectors for the delivery of nucleic acids. The compound forms liposomes that encapsulate nucleic acids and facilitate their uptake by cells. This product is for research purposes only and is not for human therapeutic use.
|
| Molecular Formula |
C41H81NO2
|
|---|---|
| Molecular Weight |
620.104
|
| Exact Mass |
619.626
|
| Elemental Analysis |
C, 79.41; H, 13.17; N, 2.26; O, 5.16
|
| CAS # |
104162-47-2
|
| PubChem CID |
11181107
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
649.7±55.0 °C at 760 mmHg
|
| Flash Point |
195.7±18.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.471
|
| LogP |
16.26
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
44
|
| Complexity |
573
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\CCCCCCCC
|
| InChi Key |
GLGLUQVVDHRLQK-WRBBJXAJSA-N
|
| InChi Code |
InChI=1S/C41H81NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-43-40-41(39-42(3)4)44-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,41H,5-18,23-40H2,1-4H3/b21-19-,22-20-
|
| Chemical Name |
N,N-dimethyl-2,3-bis[(Z)-octadec-9-enoxy]propan-1-amine
|
| Synonyms |
MBN-305A; MBN305A; MBN 305A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~161.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.03 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6126 mL | 8.0632 mL | 16.1264 mL | |
| 5 mM | 0.3225 mL | 1.6126 mL | 3.2253 mL | |
| 10 mM | 0.1613 mL | 0.8063 mL | 1.6126 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
